Type
|
Public |
---|---|
Traded as | NASDAQ: VIVO S&P 600 Component |
Industry | Medical equipment and Life Science |
Founded | Cincinnati, Ohio (1977 (1977)) |
Founder | Mr. William J. Motto |
Headquarters | Cincinnati, Ohio, United States |
Area served
|
Worldwide |
Key people
|
John A. Kraeutler (Chairman, [Executive Chairman of the Board]) |
Number of employees
|
550 |
Website |
www |
John A. Kraeutler (Chairman, [Executive Chairman of the Board])
www
www
www
www
Meridian Bioscience Inc. (Meridian)(NASDAQ: VIVO) is an international producer and distributor of a range of diagnostic test kits. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. The company consists of two segments including Diagnostics and Life Science. The focused markets of the company comprise gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease testing. It distributes the products mainly to healthcare companies and organizations in over 60 countries. The company has received the United States Food and Drug Administration (FDA) clearance and introduced its molecular amplification assay into the market.
The company was founded by William J. Motto in 1977. At the beginning, he figured out a more efficient way to ship specimen samples to testing labs. With his ideas, he received a $500 investment and set up the business based in his home in Cincinnati. This is the original form of the company. Over years of development, his business expanded and grew into Meridian.
Its product base includes testing platform and technologies, diagnostic kits and foodborne products, such as tests for Enterohemorrhagic E. coli. The testing platform was developed by DNA amplification and enzyme-relevant technologies. The company operates its business in segments including Diagnostics (U.S. and European) and Life Science. In 2010 fiscal year, the sales of diagnostic products accounted for 81% of the total sales of the company. In the same year, the company completed the acquisition of the Bioline Group.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2022 | 2022-11-10 | Future report Set alerts | |
Q3 2022 | 2022-08-05 | 0.16 | 0.16 |
Q2 2022 | 2022-05-06 | 0.66 | 0.66 |
Q1 2022 | 2022-02-04 | 0.35 | 0.35 |
Q4 2021 | 2021-11-12 | 0.24 | 0.24 |
Q3 2021 | 2021-08-06 | 0.22 | 0.22 |
Q2 2021 | 2021-05-07 | 0.57 | 0.57 |
Q1 2021 | 2021-02-05 | 0.65 | 0.65 |
Q4 2020 | 2020-11-13 | 0.10 | 0.15 |
Q3 2020 | 2020-08-07 | 0.55 | 0.64 |
2016-06-29 | Reiterated Rating | Canaccord Genuity | Hold | |
2016-04-28 | Reiterated Rating | Canaccord Genuity | Hold | |
2016-03-29 | Reiterated Rating | Robert W. Baird | Hold | $20.00 |
2016-03-28 | Upgrade | Hilliard Lyons | Neutral to Buy | $22.00 |
2016-03-28 | Reiterated Rating | Robert W. Baird | Outperform | $27.00 to $28.00 |
2016-03-28 | Reiterated Rating | Canaccord Genuity | Hold | $18.00 to $19.00 |
2016-03-21 | Downgrade | Hilliard Lyons | Buy to Neutral | |
2016-02-01 | Reiterated Rating | Canaccord Genuity | Hold | $18.00 |
2016-01-27 | Reiterated Rating | William Blair | Market Perform | |
2015-11-13 | Reiterated Rating | Canaccord Genuity | Hold | $18.00 |
2015-11-06 | Boost Price Target | Craig Hallum | Buy | $21.00 to $23.00 |
2015-09-15 | Lower Price Target | Craig Hallum | Buy | $22.00 to $21.00 |
2015-09-10 | Lower Price Target | Canaccord Genuity | Hold | $19.00 to $18.00 |
2015-08-27 | Initiated Coverage | Hilliard Lyons | Buy | $23.50 |
2015-07-27 | Lower Price Target | Canaccord Genuity | Hold | $20.00 to $19.00 |
2015-05-04 | Boost Price Target | Canaccord Genuity | Hold | $19.00 to $20.00 |
2015-04-26 | Reiterated Rating | Canaccord Genuity | Hold | $19.00 |
2015-01-26 | Set Price Target | Canaccord Genuity | Hold | $19.00 |
2015-01-23 | Upgrade | Craig Hallum | Hold to Buy | $19.00 to $22.00 |
2015-01-02 | Downgrade | Raymond James | Market Perform to Underperform | |
2015-01-02 | Downgrade | Raymond James Financial Inc. | Market Perform to Underperform | |
2014-11-06 | Downgrade | Robert W. Baird | Outperform to Neutral | $22.00 |
2014-04-25 | Lower Price Target | Cowen and Company | $24.00 to $21.00 | |
2012-07-27 | Downgrade | Canaccord Genuity | Buy to Hold | |
2011-04-25 | Upgrade | Wedbush | Underperform to Neutral | $18 to $22 |
2011-03-24 | Upgrade | Canaccord Genuity | Hold to Buy | $30 |
2010-04-07 | Initiated | Wedbush | Underperform | $18 |
2009-11-13 | Reiterated | Caris & Company | Average | $21 to $20 |
2009-07-07 | Initiated | Caris & Company | Average | $21 |
2009-03-06 | Initiated | William Blair | Mkt Perform | |
2008-10-14 | Initiated | Lazard Capital | Buy | $30 |
2008-07-21 | Upgrade | Hilliard Lyons | Neutral to Long-term Buy | |
2008-05-14 | Initiated | Susquehanna Financial | Neutral | |
2008-05-13 | Initiated | CL King | Accumulate | |
2007-04-16 | Downgrade | Hilliard Lyons | Long-term Buy to Neutral | |
2007-01-22 | Reiterated | Hilliard Lyons | Long-term Buy | $30 to $32 |
2016-06-29 | Reiterated Rating | Canaccord Genuity | Hold | |
2016-04-28 | Reiterated Rating | Canaccord Genuity | Hold | |
2016-03-29 | Reiterated Rating | Robert W. Baird | Hold | $20.00 |
2016-03-28 | Upgrade | Hilliard Lyons | Neutral to Buy | $22.00 |
2016-03-28 | Reiterated Rating | Robert W. Baird | Outperform | $27.00 to $28.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In VIVO 176 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 7.32M |
Vanguard Group, Inc | 4.93M |
BlackRock Fund Advisors | 3.32M |
RENAISSANCE TECHNOLOGIES LLC | 1.97M |
DIMENSIONAL FUND ADVISORS LP | 1.80M |
STATE STREET CORP | 1.63M |
ALLIANCEBERNSTEIN L.P. | 1.21M |
BlackRock Institutional Trust Company, N.A. | 1.16M |
GEODE CAPITAL MANAGEMENT, LLC | 0.88M |
CNH PARTNERS LLC | 0.61M |
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 0.61M |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 0.60M |
MORGAN STANLEY | 0.60M |
NORTHERN TRUST CORP | 0.54M |
FULLER & THALER ASSET MANAGEMENT, INC. | 0.54M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
KRAEUTLER JOHN A Chief Executive Officer | 0.82% (340050) | VIVO / |
LUEKE MELISSA Exec VP, CFO | 0.39% (161398) | VIVO / |
ROLIH SUSAN Sr. VP, Reg Affairs and QA | 0.38% (158589) | VIVO / |
BALDINI LAWRENCE Exec VP, Operations & IS | 0.24% (101354) | VIVO / |
MOTTO WILLIAM J Executive Chairman | 0.17% (69087) | VIVO / |
Calzavara Marco G. Pres & Managing Director, MBE | 0.13% (54057) | VIVO / |
Johnson Marviette D. VP, Human Resources | 0.11% (46670) | VIVO / |
Elagin Vecheslav A Sr VP, Research & Development | 0.11% (45989) | VIVO / |
EBERLY RICHARD Exec VP, Chief Commercial Off. | 0.10% (43348) | VIVO / |
Kenny John P. Chief Executive Officer | 0.09% (38000) | VIVO / |
Shaughnessy Michael C. EVP, Pres Meridian Global Dx | 0.07% (29000) | VIVO / |
Winslow Amy EVP, Pres & CEO of Magellan | 0.05% (22500) | VIVO / |
READY ROBERT J | 0.05% (18901) | LYTS / VIVO / |
PHILLIPS DAVID | 0.03% (12500) | CTAS / VIVO / |
Sazdanoff Catherine | 0.02% (7700) | VIVO / |
Ellingwood Dwight E | 0.01% (5980) | VIVO / |
McIlwraith John | 0.01% (4000) | VIVO / |